Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:11:02.227Z.
Calculation as of: 2026-10-06T14:11:02.227Z.
Quote observation: 2026-10-06T14:10:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0d16669f7a2c0e1646e6313a61118319ccaec2b3022f40527d46d929c834448
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$236.90M
EBITDA Yield
N/A
TTM Avg
6.75%
3Y Avg
3.64%
5Y Avg
3.64%
Market Cap
$243.66M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$243.81M
EBITDA Yield
N/A
TTM Avg
3.52%
3Y Avg
3.58%
5Y Avg
4.02%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioAge Labs Inc. (BIOA) | $234.93M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $231.69M | N/A | 0.97% | 0.50% | 0.50% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.90M | N/A | 6.75% | 3.64% | 3.64% |
| Galectin Therapeutics Inc. (GALT)vs › | $239.06M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $240.50M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $240.76M | 7.72% | 5.41% | 5.10% | 3.84% |
| InflaRx N.V. (IFRX)vs › | $241.56M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.66M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | N/A | 3.52% | 3.58% | 4.02% |
| Keros Therapeutics, Inc. (KROS)vs › | $225.44M | N/A | 143.11% | 143.11% | 143.11% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
